Cargando…
Delayed Presentation of Acute Generalized Exanthematous Pustulosis Following Treatment with Cefepime in a Patient with COVID-19 without the Use of Hydroxychloroquine
Patient: Male, 78-year-old Final Diagnosis: Acute generalized exanthematous pustulosis (AGEP) Symptoms: Rash Medication:— Clinical Procedure: — Specialty: Allergology • Infectious Diseases OBJECTIVE: Rare disease BACKGROUND: Acute generalized exanthematous pustulosis (AGEP) is a rare exanthem charac...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scientific Literature, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592336/ https://www.ncbi.nlm.nih.gov/pubmed/33097683 http://dx.doi.org/10.12659/AJCR.926901 |
_version_ | 1783601166003732480 |
---|---|
author | Haraszti, Samantha Sendil, Selin Jensen, Nichole |
author_facet | Haraszti, Samantha Sendil, Selin Jensen, Nichole |
author_sort | Haraszti, Samantha |
collection | PubMed |
description | Patient: Male, 78-year-old Final Diagnosis: Acute generalized exanthematous pustulosis (AGEP) Symptoms: Rash Medication:— Clinical Procedure: — Specialty: Allergology • Infectious Diseases OBJECTIVE: Rare disease BACKGROUND: Acute generalized exanthematous pustulosis (AGEP) is a rare exanthem characterized by the abrupt onset of numerous small, non-follicular, sterile pustules arising on an erythematous base. AGEP is often associated with medications; however, it has also been connected to various viral infections including cytomegalovirus, parvo-virus B19, and Epstein-Barr virus. Coronavirus disease 2019 (COVID-19) has been associated with a variety of skin findings, including erythematous or patchy rash, urticaria, hives, blisters, petechiae, livedo reticularis, and even AGEP in a patient undergoing treatment with hydroxychloroquine. CASE REPORT: A 78-year-old man with a past medical history of benign prostatic hyperplasia, coronary artery disease, and atrial fibrillation presented with septic shock secondary to a urinary tract infection. On day 7 of treatment with cefepime, he became febrile and developed a pustular rash and persistent hypotension without any respiratory symptoms. Subsequently, he was diagnosed with COVID-19. Skin biopsy of the rash revealed AGEP. CONCLUSIONS: AGEP is an uncommon cutaneous eruption often triggered by medications and viruses. AGEP is thought to be mediated by pro-inflammatory cells and cytokines. This report describes an unusual presentation of AGEP following treatment with cefepime for a urinary tract infection in a 78-year-old man who was found to be positive for SARS-CoV-2 infection, but was not treated with hydroxychloroquine. Although AGEP has been described in association with some viral infections, it is more commonly a drug-associated dermatosis, commonly seen during treatment with antibiotics. As in this case, AGEP usually resolves after discontinuation of the offending antibiotic. |
format | Online Article Text |
id | pubmed-7592336 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | International Scientific Literature, Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-75923362020-10-28 Delayed Presentation of Acute Generalized Exanthematous Pustulosis Following Treatment with Cefepime in a Patient with COVID-19 without the Use of Hydroxychloroquine Haraszti, Samantha Sendil, Selin Jensen, Nichole Am J Case Rep Articles Patient: Male, 78-year-old Final Diagnosis: Acute generalized exanthematous pustulosis (AGEP) Symptoms: Rash Medication:— Clinical Procedure: — Specialty: Allergology • Infectious Diseases OBJECTIVE: Rare disease BACKGROUND: Acute generalized exanthematous pustulosis (AGEP) is a rare exanthem characterized by the abrupt onset of numerous small, non-follicular, sterile pustules arising on an erythematous base. AGEP is often associated with medications; however, it has also been connected to various viral infections including cytomegalovirus, parvo-virus B19, and Epstein-Barr virus. Coronavirus disease 2019 (COVID-19) has been associated with a variety of skin findings, including erythematous or patchy rash, urticaria, hives, blisters, petechiae, livedo reticularis, and even AGEP in a patient undergoing treatment with hydroxychloroquine. CASE REPORT: A 78-year-old man with a past medical history of benign prostatic hyperplasia, coronary artery disease, and atrial fibrillation presented with septic shock secondary to a urinary tract infection. On day 7 of treatment with cefepime, he became febrile and developed a pustular rash and persistent hypotension without any respiratory symptoms. Subsequently, he was diagnosed with COVID-19. Skin biopsy of the rash revealed AGEP. CONCLUSIONS: AGEP is an uncommon cutaneous eruption often triggered by medications and viruses. AGEP is thought to be mediated by pro-inflammatory cells and cytokines. This report describes an unusual presentation of AGEP following treatment with cefepime for a urinary tract infection in a 78-year-old man who was found to be positive for SARS-CoV-2 infection, but was not treated with hydroxychloroquine. Although AGEP has been described in association with some viral infections, it is more commonly a drug-associated dermatosis, commonly seen during treatment with antibiotics. As in this case, AGEP usually resolves after discontinuation of the offending antibiotic. International Scientific Literature, Inc. 2020-10-24 /pmc/articles/PMC7592336/ /pubmed/33097683 http://dx.doi.org/10.12659/AJCR.926901 Text en © Am J Case Rep, 2020 This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) ) |
spellingShingle | Articles Haraszti, Samantha Sendil, Selin Jensen, Nichole Delayed Presentation of Acute Generalized Exanthematous Pustulosis Following Treatment with Cefepime in a Patient with COVID-19 without the Use of Hydroxychloroquine |
title | Delayed Presentation of Acute Generalized Exanthematous Pustulosis Following Treatment with Cefepime in a Patient with COVID-19 without the Use of Hydroxychloroquine |
title_full | Delayed Presentation of Acute Generalized Exanthematous Pustulosis Following Treatment with Cefepime in a Patient with COVID-19 without the Use of Hydroxychloroquine |
title_fullStr | Delayed Presentation of Acute Generalized Exanthematous Pustulosis Following Treatment with Cefepime in a Patient with COVID-19 without the Use of Hydroxychloroquine |
title_full_unstemmed | Delayed Presentation of Acute Generalized Exanthematous Pustulosis Following Treatment with Cefepime in a Patient with COVID-19 without the Use of Hydroxychloroquine |
title_short | Delayed Presentation of Acute Generalized Exanthematous Pustulosis Following Treatment with Cefepime in a Patient with COVID-19 without the Use of Hydroxychloroquine |
title_sort | delayed presentation of acute generalized exanthematous pustulosis following treatment with cefepime in a patient with covid-19 without the use of hydroxychloroquine |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7592336/ https://www.ncbi.nlm.nih.gov/pubmed/33097683 http://dx.doi.org/10.12659/AJCR.926901 |
work_keys_str_mv | AT harasztisamantha delayedpresentationofacutegeneralizedexanthematouspustulosisfollowingtreatmentwithcefepimeinapatientwithcovid19withouttheuseofhydroxychloroquine AT sendilselin delayedpresentationofacutegeneralizedexanthematouspustulosisfollowingtreatmentwithcefepimeinapatientwithcovid19withouttheuseofhydroxychloroquine AT jensennichole delayedpresentationofacutegeneralizedexanthematouspustulosisfollowingtreatmentwithcefepimeinapatientwithcovid19withouttheuseofhydroxychloroquine |